ascopubs.org

Letetresgene Autoleucel: A Milestone in Treatment of Myxoid/Round Cell Liposarcoma

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma

Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials In this pilot study, we assessed the ...
Cure Today

T-Cell Therapy With Lete-Cel Demonstrates Efficacy in Sarcoma Subtypes

Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...
Nasdaq

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...
Targeted Oncology

IGF-1 and GLP-1 Shape Liposarcoma Development, Presenting Potential Targets

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...